{
    "nctId": "NCT00035594",
    "briefTitle": "Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy",
    "officialTitle": "A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects With Advanced Breast Cancer Treated With Single Agent Docetaxel",
    "overallStatus": "COMPLETED",
    "conditions": "Neutropenia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 928,
    "primaryOutcomeMeasure": "Proportion of subjects developing febrile neutropenia",
    "eligibilityCriteria": "* Advanced breast cancer\n* 18 years of age or older\n* Patients who will be receiving Taxotere (docetaxel) chemotherapy",
    "sex": "N/A",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}